创新药出海进入兑现阶段，恒生创新药ETF（159316）标的指数年内涨幅超64%

Core Viewpoint - The Chinese innovative pharmaceutical sector has shown significant performance in 2025, with the Hang Seng Innovative Drug Index increasing by over 64% throughout the year, indicating a shift from narrative to actual realization in the industry [1] Group 1: Market Performance - On December 31, 2025, various indices related to the pharmaceutical sector experienced declines, with the CSI Innovative Drug Industry Index down by 0.4%, the CSI Biotech Theme Index down by 0.7%, the CSI 300 Healthcare Index down by 0.8%, the Hang Seng Hong Kong Stock Connect Innovative Drug Index down by 1.1%, and the CSI Hong Kong Stock Connect Healthcare Comprehensive Index down by 1.4% [1] - The latest scale of the Hang Seng Innovative Drug ETF (159316) has exceeded 4 billion yuan [1] Group 2: Industry Insights - According to Zhongtai Securities, the current innovative drug market differs from the period of 2019-2021, as the transition from narrative to actual realization in overseas markets has led to record-high transaction amounts, reflecting a leap in China's innovative capabilities from quantity to quality [1] - Continuous support from domestic policies for innovative drugs has been observed, including the introduction of a commercial insurance directory, which has opened up new payment avenues [1]